Janine E. Polifka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Janine E. Polifka has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Alan G. Fantel
Department of Pediatrics; University of Washington; Seattle Washington
2 shared publicationsGodfrey P. Oakley
Department of Epidemiology, Rollins School of Public Health; Emory University; Atlanta Georgia
2 shared publications- Jan Marshall Friedman
Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada; BC Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada
2 shared publications Cynthia R. Dolan
Inland Northwest Genetics Clinic, Spokane, Washington 99210
1 shared publication- Elaine M. Faustman
Institute for Risk Analysis and Risk Communication, University of Washington, Seattle, WA, USA; Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA
1 shared publication - Hamid Ferdosi
Center for Epidemiology and Environmental Health (CEOH, LLC), Washington, DC 20016, USA
1 shared publication
Latest Publications
- 4 May 2023
- Published by Wiley in Birth Defects Research
- Vol. 115 (14) , 1294-1303
Personal reminiscences and reflections: In Memoriam of Robert L. Brent
- 4 May 2023
- Published by Wiley in Birth Defects Research
- Vol. 115 (14) , 1294-1303
Personal reminiscences and reflections: In Memoriam of Robert L. Brent
- 5 March 2023
- Published by Wiley in Birth Defects Research
- Vol. 115 (14) , 1227-1242
Bob Brent: Scientist, physician, scholar, teacher, mentor, and mensch
- 5 March 2023
- Published by Wiley in Birth Defects Research
- Vol. 115 (14) , 1227-1242
Bob Brent: Scientist, physician, scholar, teacher, mentor, and mensch
- Open Access
- 21 March 2019
- Published by Oxford University Press (OUP) in International Health
- Vol. 11 (6) , 513-519
Assessment of developmental risk information on medicines for inclusion on the WHO’s Essential Medicines List
Background: The WHO develops biannually an Essential Medicines List (EML) of medications proposed for national formularies to be safe, effective and cost-effective. This satisfies the priority healthcare needs of most adult populations, but it does not consider the unique toxicological risks that occur from exposures during pregnancy. Methods: Developmental toxicity risk information for the 451 specific agents on the 2017 EML were identified from four well-recognized compendia of teratological assessments. On this basis, each agent was classified as having known, suggested, or little to no developmental risk, or as having insufficient information. Results: Thirteen (3%) EML agents posed known developmental risks, and 115 (25%) had evidence suggesting risk. For 170 (38%) agents, there was little or no evidence of such risk. Thus, risk classification could be determined for 66% of the agents. For an additional 153 (34%) agents, the information was insufficient for classification. Conclusion: It is feasible to expand the classification of most of the EML agents to include the risks from exposure during pregnancy.
- 21 March 2019
- Published by Oxford University Press (OUP) in International Health
- Vol. 11 (6) , 513-519
Open AccessAssessment of developmental risk information on medicines for inclusion on the WHO’s Essential Medicines List
Background: The WHO develops biannually an Essential Medicines List (EML) of medications proposed for national formularies to be safe, effective and cost-effective. This satisfies the priority healthcare needs of most adult populations, but it does not consider the unique toxicological risks that occur from exposures during pregnancy. Methods: Developmental toxicity risk information for the 451 specific agents on the 2017 EML were identified from four well-recognized compendia of teratological assessments. On this basis, each agent was classified as having known, suggested, or little to no developmental risk, or as having insufficient information. Results: Thirteen (3%) EML agents posed known developmental risks, and 115 (25%) had evidence suggesting risk. For 170 (38%) agents, there was little or no evidence of such risk. Thus, risk classification could be determined for 66% of the agents. For an additional 153 (34%) agents, the information was insufficient for classification. Conclusion: It is feasible to expand the classification of most of the EML agents to include the risks from exposure during pregnancy.
- 1 May 2017
- Published by Wiley in Birth Defects Research
- Vol. 109 (8) , 533-534
In Memoriam: Thomas H. Shepard, M.D., Pioneer in Embryology and Teratology
- 1 May 2017
- Published by Wiley in Birth Defects Research
- Vol. 109 (8) , 533-534
In Memoriam: Thomas H. Shepard, M.D., Pioneer in Embryology and Teratology
- 20 March 2017
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 173 (6) , 1465-1466
Thomas H. Shepard, M.D., pioneer in embryology and teratology
Dr. Thomas H. Shepard died on October 3, 2016 at the age of 93. He was a major figure in the fields of teratology, embryonic and fetal pathology, and pediatrics. He was beloved by his colleagues as he was by the many students and fellows whom he taught, mentored and befriended. His contributions to teratology are extraordinary and he is greatly missed.
- 20 March 2017
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 173 (6) , 1465-1466
Thomas H. Shepard, M.D., pioneer in embryology and teratology
Dr. Thomas H. Shepard died on October 3, 2016 at the age of 93. He was a major figure in the fields of teratology, embryonic and fetal pathology, and pediatrics. He was beloved by his colleagues as he was by the many students and fellows whom he taught, mentored and befriended. His contributions to teratology are extraordinary and he is greatly missed.
- 17 July 2012
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 94 (8) , 576-598
Is there an embryopathy associated with first‐trimester exposure to angiotensin‐converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence
Drugs that interfere with the renin‐angiotensin system, such as angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are widely used to manage hypertension and heart failure. Adequate functioning of the RAS is essential for normal fetal kidney development. The potential for ACEIs and ARBs to impair fetal and neonatal renal function if taken after the first trimester of pregnancy has been well documented. Although these drugs were not found to be teratogenic in animals, until recently little was known about the teratogenic effects of ACEIs and ARBs in humans when exposure was limited to the first trimester of pregnancy. New evidence from epidemiologic studies indicates that there may be an elevated teratogenic risk when these drugs are taken during the first trimester of pregnancy. However, this elevated risk does not appear to be specific to ACEIs and ARBs, but is instead related to maternal factors and diseases that typically coexist with hypertension in pregnancy, such as diabetes, advanced maternal age, and obesity. Women who become pregnant while being treated with an ACEI or ARB should be advised to avoid exposure to these drugs during the second and third trimesters of pregnancy by switching to a different class of antihypertensive drugs between weeks 8 and 10 after conception. Birth Defects Research (Part A) 94:576–598, 2012.
- 17 July 2012
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 94 (8) , 576-598
Is there an embryopathy associated with first‐trimester exposure to angiotensin‐converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence
Drugs that interfere with the renin‐angiotensin system, such as angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are widely used to manage hypertension and heart failure. Adequate functioning of the RAS is essential for normal fetal kidney development. The potential for ACEIs and ARBs to impair fetal and neonatal renal function if taken after the first trimester of pregnancy has been well documented. Although these drugs were not found to be teratogenic in animals, until recently little was known about the teratogenic effects of ACEIs and ARBs in humans when exposure was limited to the first trimester of pregnancy. New evidence from epidemiologic studies indicates that there may be an elevated teratogenic risk when these drugs are taken during the first trimester of pregnancy. However, this elevated risk does not appear to be specific to ACEIs and ARBs, but is instead related to maternal factors and diseases that typically coexist with hypertension in pregnancy, such as diabetes, advanced maternal age, and obesity. Women who become pregnant while being treated with an ACEI or ARB should be advised to avoid exposure to these drugs during the second and third trimesters of pregnancy by switching to a different class of antihypertensive drugs between weeks 8 and 10 after conception. Birth Defects Research (Part A) 94:576–598, 2012.
- 29 January 2003
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 67 (1) , 8-12
Developmental toxicity of ribavirin/IFα combination therapy: Is the label more dangerous than the drugs?
- 29 January 2003
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 67 (1) , 8-12
Developmental toxicity of ribavirin/IFα combination therapy: Is the label more dangerous than the drugs?
- 6 August 2002
- Vol. 167 (3) , 265-73
Medical genetics: 1. Clinical teratology in the age of genomics.
Teratogenic exposures are those that can cause an embryo or fetus to develop abnormally. Several factors determine whether an agent is teratogenic, including the gestational timing of the exposure, as well as the dose, route and nature of the agent itself. We review the general concepts of teratogenesis, as well as known genetic susceptibilities to teratogenic effects, with a special focus on antiepileptic drugs. We discuss general principles of risk counselling and risk reduction, and we describe several long-known teratogens, as well as several exposures recognized only recently to have teratogenic potential.
- 6 August 2002
- Vol. 167 (3) , 265-73
Medical genetics: 1. Clinical teratology in the age of genomics.
Teratogenic exposures are those that can cause an embryo or fetus to develop abnormally. Several factors determine whether an agent is teratogenic, including the gestational timing of the exposure, as well as the dose, route and nature of the agent itself. We review the general concepts of teratogenesis, as well as known genetic susceptibilities to teratogenic effects, with a special focus on antiepileptic drugs. We discuss general principles of risk counselling and risk reduction, and we describe several long-known teratogens, as well as several exposures recognized only recently to have teratogenic potential.
- 11 April 2002
- Published by Wiley in Teratology
- Vol. 65 (5) , 240-261
Teratogen update: Azathioprine and 6‐mercaptopurine
- 11 April 2002
- Published by Wiley in Teratology
- Vol. 65 (5) , 240-261
Teratogen update: Azathioprine and 6‐mercaptopurine
- 1 April 2002
- Published by Elsevier in Toxicology
- Vol. 173 (1-2) , 35-65
Developmental toxicity: web resources for evaluating risk in humans
- 1 April 2002
- Published by Elsevier in Toxicology
- Vol. 173 (1-2) , 35-65
Developmental toxicity: web resources for evaluating risk in humans